INVO Selects Kansas City as additional INVO Center Location
INVO Bioscience announced plans to open a new INVO Center in Kansas City, Missouri, enhancing its expansion strategy aimed at increasing access to fertility care through its INVOcell medical device. The new center aligns with the company's goal to address the significant demand for fertility treatments in areas with limited options, as Kansas City has approximately 33,000 individuals facing infertility issues. Currently operating three INVO Centers, INVO aims to provide efficient and affordable fertility solutions nationwide.
- The opening of the Kansas City INVO Center supports the company's expansion strategy.
- Kansas City has a potential patient base of 33,000 individuals suffering from infertility.
- The INVOcell solution offers an effective and cost-efficient alternative to traditional IVF treatments.
- None.
U.S. Market Expansion Continues as Planned
SARASOTA, Fla., April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced plans to open an INVO Center in Kansas City, Missouri. The Kansas City INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell® solution. The Company currently has three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to open in the San Francisco and Tampa areas.
"We are excited to announce Kansas City as another ideal location for an INVO Center," commented Steve Shum, CEO of INVO. "We are refining the process involved in opening an INVO Center and are executing these initiatives simultaneously to improve operational timelines and revenue ramp. This new INVO Center is consistent with our stated expansion plans and represents a key component of our strategy to expand access to advanced fertility services for the significantly underserved patient population in the U.S. and abroad."
The Company evaluates several criteria and data points as part of its efforts to identify markets suitable for INVO Centers. Based on an analysis of current population statistics, we believe that Kansas City may have upwards of 33,000 patients suffering with Infertility. With an estimated 1,500 IVF treatments annually, there exists a large gap of available care to treat local demand. Similar to other INVO Centers, the Company expects to engage physician partners to support its efforts in the Kansas City market.
About INVO Bioscience
We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-selects-kansas-city-as-additional-invo-center-location-301525484.html
SOURCE INVO Bioscience, Inc.
FAQ
What is the purpose of the new INVO Center in Kansas City?
How many INVO Centers are currently operational?
What is the estimated number of infertility patients in Kansas City?
What is the significance of the INVOcell device?
What is the expected annual IVF treatment volume in Kansas City?
